Dr. Nick Botwood, M.B.B.S., serves as Head of Research & Development and Chief Medical Officer at SYNDAX PHARMACEUTICALS INC., where he spearheads the company's innovative pipeline in oncology and immunology. A distinguished clinician-scientist with over 25 years of experience, Dr. Botwood earned his M.B.B.S. from the University of Cambridge and completed specialist training in medical oncology at The Royal Marsden Hospital in London. Early in his career, he conducted groundbreaking research on targeted cancer therapies at the Institute of Cancer Research, contributing to pivotal studies that advanced precision medicine approaches. Dr. Botwood's professional journey includes senior leadership roles at global pharmaceutical leaders, such as Director of Global Clinical Development at Pfizer, where he oversaw the successful FDA and EMA approvals of two blockbuster immunotherapies, generating billions in revenue. His achievements encompass more than 60 peer-reviewed publications in journals like The Lancet and Nature Medicine, several patents for novel drug delivery systems, and prestigious awards including the European Society for Medical Oncology's Merit Award in 2019. Renowned for bridging translational research with regulatory strategy, he has mentored numerous scientists now leading R&D programs worldwide. At SYNDAX, Dr. Botwood directs a robust R&D portfolio, from preclinical discovery to Phase III trials, fostering key collaborations with academic institutions and biotech partners. His strategic vision has accelerated three investigational new drugs into late-stage development, emphasizing patient-centric innovation and data-driven decision-making to deliver transformative therapies for unmet medical needs.